256 related articles for article (PubMed ID: 8323383)
1. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial.
Kruize AA; Hené RJ; Kallenberg CG; van Bijsterveld OP; van der Heide A; Kater L; Bijlsma JW
Ann Rheum Dis; 1993 May; 52(5):360-4. PubMed ID: 8323383
[TBL] [Abstract][Full Text] [Related]
2. Treatment of primary Sjögren's syndrome with hydroxychloroquine.
Fox RI; Chan E; Benton L; Fong S; Friedlaender M; Howell FV
Am J Med; 1988 Oct; 85(4A):62-7. PubMed ID: 3177432
[TBL] [Abstract][Full Text] [Related]
3. Prednisone and piroxicam for treatment of primary Sjögren's syndrome.
Fox PC; Datiles M; Atkinson JC; Macynski AA; Scott J; Fletcher D; Valdez IH; Kurrasch RH; Delapenha R; Jackson W
Clin Exp Rheumatol; 1993; 11(2):149-56. PubMed ID: 8508556
[TBL] [Abstract][Full Text] [Related]
4. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.
Fox RI; Dixon R; Guarrasi V; Krubel S
Lupus; 1996 Jun; 5 Suppl 1():S31-6. PubMed ID: 8803908
[TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers.
Tishler M; Yaron I; Shirazi I; Yaron M
Ann Rheum Dis; 1999 Apr; 58(4):253-6. PubMed ID: 10364906
[TBL] [Abstract][Full Text] [Related]
6. Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.
Wang SQ; Zhang LW; Wei P; Hua H
BMC Musculoskelet Disord; 2017 May; 18(1):186. PubMed ID: 28499370
[TBL] [Abstract][Full Text] [Related]
7. Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.
Yoon CH; Lee HJ; Lee EY; Lee EB; Lee WW; Kim MK; Wee WR
J Korean Med Sci; 2016 Jul; 31(7):1127-35. PubMed ID: 27366013
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the clinical efficacy of yiqi fumai injection combined hydroxychloroquine sulfate tablet for treating Sjogren's syndrome].
Chen FY; Xue B; Wang H
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Dec; 32(12):1621-3. PubMed ID: 23469599
[TBL] [Abstract][Full Text] [Related]
9. Recognition and management of Sjögren's syndrome: strategies for the advanced practice nurse.
Vale DL
Nurs Clin North Am; 2000 Mar; 35(1):267-78. PubMed ID: 10673580
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
[TBL] [Abstract][Full Text] [Related]
11. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Juarez M; Diaz N; Johnston GI; Nayar S; Payne A; Helmer E; Cain D; Williams P; Devauchelle-Pensec V; Fisher BA; Giacomelli R; Gottenberg JE; Guggino G; Kvarnström M; Mariette X; Ng WF; Rosas J; Sánchez Bursón J; Triolo G; Barone F; Bowman SJ
Rheumatology (Oxford); 2021 Mar; 60(3):1364-1375. PubMed ID: 32949140
[TBL] [Abstract][Full Text] [Related]
14. Effect of Chinese herbal medicines for nourishing yin, supplementing qi, and activating blood on reproductive endocrine activity and immune functions in patients with primary Sjogren's syndrome.
Wu GL; Wu NY; Li TY; Fan YS; Yu GY; Lu WW
Chin J Integr Med; 2015 Oct; 21(10):778-83. PubMed ID: 26525549
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase.
Dawson LJ; Caulfield VL; Stanbury JB; Field AE; Christmas SE; Smith PM
Rheumatology (Oxford); 2005 Apr; 44(4):449-55. PubMed ID: 15590764
[TBL] [Abstract][Full Text] [Related]
16. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
Gottenberg JE; Ravaud P; Puéchal X; Le Guern V; Sibilia J; Goeb V; Larroche C; Dubost JJ; Rist S; Saraux A; Devauchelle-Pensec V; Morel J; Hayem G; Hatron P; Perdriger A; Sene D; Zarnitsky C; Batouche D; Furlan V; Benessiano J; Perrodeau E; Seror R; Mariette X
JAMA; 2014 Jul; 312(3):249-58. PubMed ID: 25027140
[TBL] [Abstract][Full Text] [Related]
17. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
Hu W; Qian X; Guo F; Zhang M; Lyu C; Tao J; Gao Z; Zhou Z
Chin Med J (Engl); 2014; 127(15):2721-6. PubMed ID: 25146603
[TBL] [Abstract][Full Text] [Related]
18. Clinical and immunological factors associated with low lacrimal and salivary flow rate in patients with primary Sjögren's syndrome.
Pijpe J; Kalk WW; Vissink A
J Rheumatol; 2003 Jan; 30(1):206-7; author reply 207. PubMed ID: 12508418
[No Abstract] [Full Text] [Related]
19. Progression of salivary gland dysfunction in patients with Sjogren's syndrome.
Pijpe J; Kalk WW; Bootsma H; Spijkervet FK; Kallenberg CG; Vissink A
Ann Rheum Dis; 2007 Jan; 66(1):107-12. PubMed ID: 16728458
[TBL] [Abstract][Full Text] [Related]
20. Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sjögren's syndrome.
van der Heijden EH; Hartgring SA; Kruize AA; Radstake TR; van Roon JA
Expert Rev Clin Immunol; 2019 Jul; 15(7):801-808. PubMed ID: 31192747
[No Abstract] [Full Text] [Related]
[Next] [New Search]
